AI
ADCT icon

Atom Investors’s ADC Therapeutics ADCT Stock Holding History

Atom Investors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,131
Closed -$52.5K – 560
2025
Q3 		$52.5K Buy
+13,131
New +$41.4K ﹤0.01% 576
2024
Q3 		– Sell
-322,289
Closed -$1.02M – 460
2024
Q2 		$1.02M Buy
+322,289
New +$1.28M 0.1% 248

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Atom Investors's ADCT Position: Q4 2025 in Review

Atom Investors sold out of ADC Therapeutics (ADCT) in Q4 2025, closing a stake of 13,131 shares — an estimated $52.5K sold.

Atom Investors first reported a position in ADCT in Q2 2024 and held it in 2 quarters. The position peaked at $1.02M in Q2 2024. 115 funds tracked by Wall St. Rank hold ADCT as of Q4 2025.

  • Atom Investors reported no remaining ADC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 13,131 ADC Therapeutics shares in Q4 2025, an estimated $52.5K.
  • Atom Investors first reported a position in ADC Therapeutics in Q2 2024 and held it in 2 quarters.
  • Atom Investors's ADC Therapeutics position peaked at $1.02M in Q2 2024.
  • 115 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.